AstraZeneca Imfinzi gets FDA priority review

The filing is backed by phase III VOLGA data showing statistically significant and clinically relevant improvements in event-free survival and overall survival versus surgery alone or surgery followed by an approved adjuvant therapy. AstraZeneca said no new safety signals were seen and that the safety profile was consistent with the known effects of the drugs.

The target population is commercially meaningful. AstraZeneca says muscle-invasive bladder cancer accounts for about one in four bladder cancer cases, while as many as 50% of patients cannot receive cisplatin-based chemotherapy because of kidney problems or other comorbidities. That leaves a sizable group of patients with limited frontline options if the combination is cleared.

The study enrolled 695 patients across 182 centers in 25 countries, and similar regulatory reviews are already under way in the European Union, Japan and other markets. Imfinzi is already approved in more than 50 countries for selected patients in this setting, and AstraZeneca says more than 470,000 patients have received the drug since its first approval in 2017.

The news adds another catalyst to AstraZeneca’s oncology pipeline at a time when the company is trying to extend the life of its immunotherapy and ADC portfolio. Shares were recently up 0.69% in Tradegate trading, while U.S. biotech ETFs such as XBI and IBB have been trading near their 50-day moving averages, reflecting a market that is still selective on drug-development risk but responsive to clear regulatory and clinical wins.

The next key date is the FDA decision in late 2026, with the main upside for AstraZeneca hinging on whether the agency converts the faster review into an approval and a new treatment standard for patients who cannot tolerate cisplatin.